SRT2379

DRUG3 trials

Sponsors

GlaxoSmithKline, Sirtris, a GSK Company

Conditions

Diabetes Mellitus, Type 2Sepsis

Phase 1

A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers

CompletedNCT01018628

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2009-12-07End: 2010-08-06Updated: 2017-06-09

Effect of SRT2379 on Endotoxin-Induced Inflammation

CompletedNCT01262911

Sirtris, a GSK CompanySepsis

Start: 2011-02-17End: 2011-04-26Updated: 2017-08-04

Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

CompletedNCT01416376

Sirtris, a GSK CompanySepsis

Start: 2011-08-30End: 2011-12-12Updated: 2017-06-15